Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
April 14, 2026

Povetacicept (alpn-303) for treatment of primary IgA nephropathy as of April 2026

MARA Rating Company April 14, 2026

Lifyorli for platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Prior Bevacizumab as of April 2026

MARA Rating Company April 14, 2026

Avlayah / tividenofusp alfa-eknm for in treating neurologic manifestations of Hunter syndrome as of April 2026

MARA Rating Company April 14, 2026

Lynavoy / linerixibat for cholestatic pruritus associated with primary biliary cholangitis as of April 2026

MARA Rating Company April 14, 2026

Anitocabtagene autoleucel for relapsed or refractory multiple myeloma as of April 2026

MARA Rating Company April 14, 2026

Baxdrostat for treatment-Resistant Hypertension as of April 2026

MARA Rating Company April 14, 2026

Brepocitinib / pf-06700841 for dermatomyositis as of April 2026

MARA Rating Company April 14, 2026

Camizestrant / azd9833 for hR-positive, HER2-negative advanced breast cancer as of April 2026

MARA Rating Company April 14, 2026

Felzartamab for treating Antibody_Mediated Rejection in Kidney Transplant Patients as of April 2026

MARA Rating Company April 14, 2026

Icotyde for treating moderate-to-severe plaque psoriasis in adults and adolescents aged 12+ as of April 2026

MARA Rating Company April 14, 2026